BioAtla Inc. (BCAB) Financial Statements (2024 and earlier)

Company Profile

Business Address 11085 TORREYANA ROAD
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments111,471215,507244,979
Cash and cash equivalents111,471215,507244,979
Prepaid expense   
Other undisclosed current assets4,9354,9242,313
Total current assets:116,406220,431247,292
Noncurrent Assets
Operating lease, right-of-use asset1,4952,4233,300
Property, plant and equipment1,6032,7283,676
Other noncurrent assets154154154
Total noncurrent assets:3,2525,3057,130
TOTAL ASSETS:119,658225,736254,422
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:26,72021,61018,424
Employee-related liabilities2,671
Accounts payable3,8194,2311,179
Accrued liabilities4,6554,7301,073
Other undisclosed accounts payable and accrued liabilities18,24612,64913,501
Other undisclosed current liabilities1,6241,5211,389
Total current liabilities:28,34423,13119,813
Noncurrent Liabilities
Long-term debt and lease obligation:   3,982
Liabilities, other than long-term debt8362,460 
Operating lease, liability8362,4603,982
Other undisclosed noncurrent liabilities19,80619,80615,824
Total noncurrent liabilities:20,64222,26623,788
Total liabilities:48,98645,39743,601
Equity
Equity, attributable to parent, including:70,672180,339210,821
Common stock55 
Additional paid in capital486,930473,135397,136
Accumulated deficit(416,263)(292,801)(186,319)
Other undisclosed equity, attributable to parent   4
Total equity:70,672180,339210,821
TOTAL LIABILITIES AND EQUITY:119,658225,736254,422

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues   300
Gross profit:   300
Operating expenses(129,687)(108,140)(96,690)
Other undisclosed operating loss   (50)
Operating loss:(129,687)(108,140)(96,440)
Nonoperating income
(Other Nonoperating income)
6,2251,6581,038
Interest and debt expense   690
Loss from continuing operations:(123,462)(106,482)(94,712)
Loss before gain (loss) on sale of properties:(94,712)
Net loss:(123,462)(106,482)(94,712)
Other undisclosed net loss attributable to parent   (690)
Net loss available to common stockholders, diluted:(123,462)(106,482)(95,402)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(123,462)(106,482)(94,712)
Comprehensive loss, net of tax, attributable to parent:(123,462)(106,482)(94,712)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: